FindTrial
Sign In

Cetuximab (EGFR inhibitor)

DRUG3 trials

Sponsors

Jacobio Pharmaceuticals Co., Ltd., Gruppo Oncologico del Nord-Ovest, Vanderbilt-Ingram Cancer Center

Conditions

Advanced Solid TumorCRCColorectal CancerHead and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaNSCLCRadiotracerSCC - Squamous Cell Carcinoma

Phase 1

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
CompletedNCT05002270
Jacobio Pharmaceuticals Co., Ltd.Advanced Solid Tumor, CRC, NSCLC
Start: 2021-09-03End: 2025-02-12Updated: 2026-01-13
Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma
Not yet recruitingNCT07217028
Vanderbilt-Ingram Cancer CenterHead and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Radiotracer +1
Start: 2026-04-01End: 2030-09-01Target: 60Updated: 2026-02-27

Phase 4

Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status
Not yet recruitingNCT07094893
Gruppo Oncologico del Nord-OvestColorectal Cancer
Start: 2026-04-15End: 2030-03-31Target: 280Updated: 2026-01-14

Related Papers

Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials.
2025-10-026 citations
Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors.
Journal of Clinical Oncology2024-01-2029 citations